Copyright
©2010 Baishideng.
World J Gastroenterol. Feb 7, 2010; 16(5): 547-553
Published online Feb 7, 2010. doi: 10.3748/wjg.v16.i5.547
Published online Feb 7, 2010. doi: 10.3748/wjg.v16.i5.547
Study | Treatment duration (wk) | Dosage | IBS Subtype | Sex (F/M) | Mean age (yr) | ||
Placebo | Mebeverine | Placebo | Mebeverine | ||||
Kruis et al[21] 1986 | 4-8-12-16 | Placebo open branch n = 40 | 100 mg qid n = 40 | All subtype | 23/17 | F = 43 | F = 43 |
Wheat bran (12) | Wheat bran 15 g/d n = 40 | M = 41 | M = 41 | ||||
Connell[13] 1965 | 12 | n = 20 | 400 mg/d n = 20 | All subtype | 25/15 | 40 | 40 |
Tasman-Jones[22] 1973 | 4 | n = 12 | 400 mg/d n = 12 | All subtype | 14/10 | 43 | 43 |
Berthelot et al[11] 1981 | 8 | n = 33 | 400 mg/d n = 36 | All subtype | 74/37 | 56 | 56 |
Secco et al[19] 1983 | 4 | n = 15 | 400 mg/d n= 15 | All subtype | 15/15 | 45 | 45 |
Enck et al[23] 2005 | 16 | Placebo n = 40 | n = 40 | All subtype | 43 | 36 | |
Dietary treatment n = 40 |
- Citation: Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16(5): 547-553
- URL: https://www.wjgnet.com/1007-9327/full/v16/i5/547.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i5.547